2008, Diabetes Treatment Market

未登録の方はこちらから登録できます。

TEL．03-5812-5270
FAX．03-3831-0495
E-mail：info@spi-information.com

市場調査のご依頼、専門分野のイベント・フォーラムの開催などはシード・プランニングにて承っております。

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。

ポイント: Prevalence of undetected diabetes and type 2 diabetes; Which hypoglycemic agents will go mainstream?; Morbidity evaluation and issues to be addressed

The number of patients with undetected diabetes is expected to grow to 30 million by early 21st century.
Of all patients diagnosed with diabetes, it is estimated that one-third is receiving treatment.
In view of the global spread of the metabolic syndrome, pharmaceutical companies are accelerating antidiabetics development programs.
Would Actos reduce CV risk? Avandia is causing a big controversy across the world due to potential CV risk factors.
Antidiabetic drugs available for type 2 diabetes are commonly used in combination with other drugs. In the US and EU, however, there are a number of emerging compounding agents, which implies the countermeasures against coming patent expiries.
DPP-IV inhibitors, the next-generation antidiabetics, are getting a lot of attention.
The world’s first and second inhaled insulin from Pfizer, followed by Eli Lilly, may possibly be introduced in Japan.

Summary
1. Current status of type 2 diabetes
2. Issues to be addressed for each stage of the disease for the prevention of complications
3. Future directions for antidiabetics market and issues to be addressed
General Analysis
1. Diabetes epidemic trends
2. Patients with undetected diabetes
3. Diagnosis of diabetes
4. Treatment of diabetes
5. Future directions for antidiabetic therapies

2007/12/21

A4 / 74ページ

360,000JPY

株式会社シード・プランニング

This report is written in Japanese.
Customers who need an English version:Please contact us.

SPI Infoamtion